World’s First Human Implant of a 3D-Printed Cornea Restores Sight
December 15, 2025
Background
Sleep-related bruxism, also known as tooth grinding, is a sleep disorder characterized by the involuntary clenching, grinding, or gnashing of teeth during sleep. It is a relatively common condition that can affect both adults and children.
The potential contributing factors to bruxism include:
Epidemiology
The prevalence of sleep-related bruxism can vary depending on the population studied. The overview of the epidemiology of sleep-related bruxism includes:
Adults:
Children:
Anatomy
Pathophysiology
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
Etiology
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
Genetics
Prognostic Factors
Clinical History
The clinical presentation of sleep-related bruxism can vary depending on the age group, associated comorbidities, and the acuity of the presentation. Here are some general observations:
Age Group:
Physical Examination
Oral Examination:
Temporomandibular Joint (TMJ) Evaluation:
Additional Assessments:
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The treatment paradigm for sleep-related bruxism (tooth grinding) typically involves a combination of behavioral interventions, dental approaches, and, in some cases, pharmacological management. Here’s an overview of the treatment options:
Behavioral Interventions:
Dental Approaches:
Pharmacological Management:
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-a-non-pharmacological-approach-for-treating
Non-pharmacological approaches can be effective in managing sleep-related bruxism (tooth grinding). Here are some non-pharmacological interventions commonly used for treatment:
Behavioral Modification Techniques:
Dental Approaches:
Relaxation Techniques:
Stress Management:
Role of Muscle relaxants as an adjunctive treatment
Muscle relaxants may be prescribed as an adjunctive treatment for sleep-related bruxism (tooth grinding) when other interventions have been ineffective.
benzodiazepines: benzodiazepines, such as clonazepam and diazepam, are commonly prescribed muscle relaxants for bruxism. benzodiazepines have muscle relaxant and soothing properties, which can help reduce the intensity of tooth-grinding episodes during sleep.
baclofen: baclofen is a muscle relaxant that acts as a gamma-aminobutyric acid (GABA) agonist. It primarily treats muscle spasticity in conditions such as multiple sclerosis or spinal cord injuries.
baclofen may be considered for bruxism in specific cases where other treatments have been unsuccessful. However, the evidence for its effectiveness in bruxism is limited.
dopamine modulators for the maintenance of Bruxism
dopamine is a neurotransmitter regulating movement, reward, and pleasure in the brain. It has been suggested that dopamine dysregulation may contribute to developing or maintaining bruxism.
One dopamine modulator studied for its potential use in treating bruxism is pramipexole. pramipexole is a dopamine agonist commonly used to treat Parkinson’s disease and restless legs syndrome. Stimulating dopamine receptors modulate dopamine activity in the brain and potentially reduce bruxism symptoms.
Several studies have investigated the use of pramipexole for sleep-related bruxism, and some have reported positive outcomes in reducing bruxism episodes and associated symptoms. However, the evidence is still limited, and more research is needed to establish the effectiveness and safety of dopamine modulators in sleep-related bruxism.
Use of Botulinum toxin type A injections as a potential treatment
Botulinum toxin types A injections, such as Botox®, have been explored as a potential treatment option for bruxism, including sleep-related bruxism (tooth grinding).
Botulinum toxin is a neurotoxin that blocks the release of acetylcholine, a neurotransmitter involved in muscle contraction. Botulinum toxin injections aim to reduce the intensity and frequency of teeth grinding and clenching by temporarily weakening or paralyzing the muscles involved in bruxism.
Several studies have investigated botulinum toxin type A injections for bruxism, and the results have been mixed. Some studies have reported positive outcomes, reducing bruxism symptoms and associated pain. However, other studies have shown limited effectiveness or reported only short-term benefits.
Use of Antidepressant as Off label medication
Using antidepressants to treat sleep-related bruxism (tooth grinding) is not a standard or recommended approach. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), are primarily indicated for treating depression, anxiety disorders, and other psychiatric conditions.
While bruxism can sometimes be associated with underlying psychological factors or as a side effect of certain medications, the use of antidepressants for bruxism is considered off-label.
The use of SSRIs for bruxism is based on the understanding that serotonin dysregulation may play a role in the pathophysiology of bruxism. By increasing the availability of serotonin in the brain, SSRIs help regulate the neurotransmitter’s activity and potentially reduce bruxism symptoms.
use-of-intervention-with-a-procedure-in-treating-sleep-related-bruxism-tooth-grinding
When it comes to the treatment of sleep-related bruxism (tooth grinding), interventions with procedures are not typically the first-line approach.
However, certain procedures may be considered in severe cases where other treatments have been ineffective or if specific dental or structural issues contribute to the bruxism. Here are a few examples:
use-of-phases-in-managing-sleep-related-bruxism-tooth-grinding
The management of sleep-related bruxism (tooth grinding) typically involves different phases aimed at assessing and addressing the underlying causes and symptoms of the condition.
Evaluation and Diagnosis:
Non-pharmacological Interventions:
Pharmacological Interventions:
Ongoing Management and Monitoring:
Medication
Future Trends
Sleep-related bruxism, also known as tooth grinding, is a sleep disorder characterized by the involuntary clenching, grinding, or gnashing of teeth during sleep. It is a relatively common condition that can affect both adults and children.
The potential contributing factors to bruxism include:
The prevalence of sleep-related bruxism can vary depending on the population studied. The overview of the epidemiology of sleep-related bruxism includes:
Adults:
Children:
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
The clinical presentation of sleep-related bruxism can vary depending on the age group, associated comorbidities, and the acuity of the presentation. Here are some general observations:
Age Group:
Oral Examination:
Temporomandibular Joint (TMJ) Evaluation:
Additional Assessments:
The treatment paradigm for sleep-related bruxism (tooth grinding) typically involves a combination of behavioral interventions, dental approaches, and, in some cases, pharmacological management. Here’s an overview of the treatment options:
Behavioral Interventions:
Dental Approaches:
Pharmacological Management:
Non-pharmacological approaches can be effective in managing sleep-related bruxism (tooth grinding). Here are some non-pharmacological interventions commonly used for treatment:
Behavioral Modification Techniques:
Dental Approaches:
Relaxation Techniques:
Stress Management:
Muscle relaxants may be prescribed as an adjunctive treatment for sleep-related bruxism (tooth grinding) when other interventions have been ineffective.
benzodiazepines: benzodiazepines, such as clonazepam and diazepam, are commonly prescribed muscle relaxants for bruxism. benzodiazepines have muscle relaxant and soothing properties, which can help reduce the intensity of tooth-grinding episodes during sleep.
baclofen: baclofen is a muscle relaxant that acts as a gamma-aminobutyric acid (GABA) agonist. It primarily treats muscle spasticity in conditions such as multiple sclerosis or spinal cord injuries.
baclofen may be considered for bruxism in specific cases where other treatments have been unsuccessful. However, the evidence for its effectiveness in bruxism is limited.
dopamine is a neurotransmitter regulating movement, reward, and pleasure in the brain. It has been suggested that dopamine dysregulation may contribute to developing or maintaining bruxism.
One dopamine modulator studied for its potential use in treating bruxism is pramipexole. pramipexole is a dopamine agonist commonly used to treat Parkinson’s disease and restless legs syndrome. Stimulating dopamine receptors modulate dopamine activity in the brain and potentially reduce bruxism symptoms.
Several studies have investigated the use of pramipexole for sleep-related bruxism, and some have reported positive outcomes in reducing bruxism episodes and associated symptoms. However, the evidence is still limited, and more research is needed to establish the effectiveness and safety of dopamine modulators in sleep-related bruxism.
Botulinum toxin types A injections, such as Botox®, have been explored as a potential treatment option for bruxism, including sleep-related bruxism (tooth grinding).
Botulinum toxin is a neurotoxin that blocks the release of acetylcholine, a neurotransmitter involved in muscle contraction. Botulinum toxin injections aim to reduce the intensity and frequency of teeth grinding and clenching by temporarily weakening or paralyzing the muscles involved in bruxism.
Several studies have investigated botulinum toxin type A injections for bruxism, and the results have been mixed. Some studies have reported positive outcomes, reducing bruxism symptoms and associated pain. However, other studies have shown limited effectiveness or reported only short-term benefits.
Using antidepressants to treat sleep-related bruxism (tooth grinding) is not a standard or recommended approach. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), are primarily indicated for treating depression, anxiety disorders, and other psychiatric conditions.
While bruxism can sometimes be associated with underlying psychological factors or as a side effect of certain medications, the use of antidepressants for bruxism is considered off-label.
The use of SSRIs for bruxism is based on the understanding that serotonin dysregulation may play a role in the pathophysiology of bruxism. By increasing the availability of serotonin in the brain, SSRIs help regulate the neurotransmitter’s activity and potentially reduce bruxism symptoms.
When it comes to the treatment of sleep-related bruxism (tooth grinding), interventions with procedures are not typically the first-line approach.
However, certain procedures may be considered in severe cases where other treatments have been ineffective or if specific dental or structural issues contribute to the bruxism. Here are a few examples:
The management of sleep-related bruxism (tooth grinding) typically involves different phases aimed at assessing and addressing the underlying causes and symptoms of the condition.
Evaluation and Diagnosis:
Non-pharmacological Interventions:
Pharmacological Interventions:
Ongoing Management and Monitoring:
Sleep-related bruxism, also known as tooth grinding, is a sleep disorder characterized by the involuntary clenching, grinding, or gnashing of teeth during sleep. It is a relatively common condition that can affect both adults and children.
The potential contributing factors to bruxism include:
The prevalence of sleep-related bruxism can vary depending on the population studied. The overview of the epidemiology of sleep-related bruxism includes:
Adults:
Children:
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
The pathophysiology of sleep-related bruxism includes:
Central Nervous System (CNS) Mechanisms:
Peripheral Mechanisms:
Sleep Disorders and Arousal:
The clinical presentation of sleep-related bruxism can vary depending on the age group, associated comorbidities, and the acuity of the presentation. Here are some general observations:
Age Group:
Oral Examination:
Temporomandibular Joint (TMJ) Evaluation:
Additional Assessments:
The treatment paradigm for sleep-related bruxism (tooth grinding) typically involves a combination of behavioral interventions, dental approaches, and, in some cases, pharmacological management. Here’s an overview of the treatment options:
Behavioral Interventions:
Dental Approaches:
Pharmacological Management:
Non-pharmacological approaches can be effective in managing sleep-related bruxism (tooth grinding). Here are some non-pharmacological interventions commonly used for treatment:
Behavioral Modification Techniques:
Dental Approaches:
Relaxation Techniques:
Stress Management:
Muscle relaxants may be prescribed as an adjunctive treatment for sleep-related bruxism (tooth grinding) when other interventions have been ineffective.
benzodiazepines: benzodiazepines, such as clonazepam and diazepam, are commonly prescribed muscle relaxants for bruxism. benzodiazepines have muscle relaxant and soothing properties, which can help reduce the intensity of tooth-grinding episodes during sleep.
baclofen: baclofen is a muscle relaxant that acts as a gamma-aminobutyric acid (GABA) agonist. It primarily treats muscle spasticity in conditions such as multiple sclerosis or spinal cord injuries.
baclofen may be considered for bruxism in specific cases where other treatments have been unsuccessful. However, the evidence for its effectiveness in bruxism is limited.
dopamine is a neurotransmitter regulating movement, reward, and pleasure in the brain. It has been suggested that dopamine dysregulation may contribute to developing or maintaining bruxism.
One dopamine modulator studied for its potential use in treating bruxism is pramipexole. pramipexole is a dopamine agonist commonly used to treat Parkinson’s disease and restless legs syndrome. Stimulating dopamine receptors modulate dopamine activity in the brain and potentially reduce bruxism symptoms.
Several studies have investigated the use of pramipexole for sleep-related bruxism, and some have reported positive outcomes in reducing bruxism episodes and associated symptoms. However, the evidence is still limited, and more research is needed to establish the effectiveness and safety of dopamine modulators in sleep-related bruxism.
Botulinum toxin types A injections, such as Botox®, have been explored as a potential treatment option for bruxism, including sleep-related bruxism (tooth grinding).
Botulinum toxin is a neurotoxin that blocks the release of acetylcholine, a neurotransmitter involved in muscle contraction. Botulinum toxin injections aim to reduce the intensity and frequency of teeth grinding and clenching by temporarily weakening or paralyzing the muscles involved in bruxism.
Several studies have investigated botulinum toxin type A injections for bruxism, and the results have been mixed. Some studies have reported positive outcomes, reducing bruxism symptoms and associated pain. However, other studies have shown limited effectiveness or reported only short-term benefits.
Using antidepressants to treat sleep-related bruxism (tooth grinding) is not a standard or recommended approach. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), are primarily indicated for treating depression, anxiety disorders, and other psychiatric conditions.
While bruxism can sometimes be associated with underlying psychological factors or as a side effect of certain medications, the use of antidepressants for bruxism is considered off-label.
The use of SSRIs for bruxism is based on the understanding that serotonin dysregulation may play a role in the pathophysiology of bruxism. By increasing the availability of serotonin in the brain, SSRIs help regulate the neurotransmitter’s activity and potentially reduce bruxism symptoms.
When it comes to the treatment of sleep-related bruxism (tooth grinding), interventions with procedures are not typically the first-line approach.
However, certain procedures may be considered in severe cases where other treatments have been ineffective or if specific dental or structural issues contribute to the bruxism. Here are a few examples:
The management of sleep-related bruxism (tooth grinding) typically involves different phases aimed at assessing and addressing the underlying causes and symptoms of the condition.
Evaluation and Diagnosis:
Non-pharmacological Interventions:
Pharmacological Interventions:
Ongoing Management and Monitoring:

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
